Full-Time

Associate Director

Medical Review

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$169.4k - $266.2k/yr

+ Short-term and/or long-term incentives + 401(k) company match

Massachusetts, USA

Remote

Overnight travel of 10–20% is required, including some weekend commitments.

PharmD, PhD, MD

Category
Biology & Biotech
Required Skills
Microsoft Office
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A doctoral degree in a health sciences-related field such as a PharmD, MD, or PhD, with a thorough grasp of the pharmaceutical industry.
  • Three to five years of healthcare or related experience following award of a doctoral degree, including a minimum of two years of medical communications experience within the pharmaceutical industry.
  • Advanced oral and written communication skills, with the ability to engender trust and respect among peers, subordinates, and superiors.
  • Proficiency in highly technical and scientific language for communication with key internal and external stakeholders.
  • A firm understanding of the drug development process, including key phases, processes, and techniques used for pre- and post-marketing research studies.
  • A proven track record of teamwork, leadership, timely decision-making, and results orientation in meeting objectives.
  • Proficiency in Microsoft Office applications, including Word, Excel, PowerPoint, and Outlook.
  • Ability to drive to or fly to various meetings and client sites.
  • Overnight travel of 10–20%, including some weekend commitments.
Responsibilities
  • Deliver high-quality, balanced, and timely medical and scientific information regarding assigned products and serve as a technical and/or operational resource.
  • Provide advanced medical and scientific review for promotional materials, press releases, and sales training communications.
  • Provide advanced medical and scientific review for non-promotional medical materials and other identified materials.
  • Serve as an experienced medical and scientific resource to internal stakeholders, including Medical Teams, Brand Teams, Regulatory Advertising and Promotion, and Legal.
  • Actively participate, support, and contribute to assigned Medical, Regulatory, and Legal cross-functional teams in promotional review.
  • Serve as an experienced medical resource and collaborator for other non-medical internal stakeholders regarding medical review and other identified commercial and corporate needs.
  • Grant formal approval through signature authority for cross-functional promotional review activities, including providing strategic scientific consultation on brand messages and content, reviewing promotional materials for content and accuracy, and coordinating the development, review, and approval of clinical data on file to support promotional claims.
  • Maintain current awareness of industry standards and regulations, share insights, and apply best practices to promotional review and related activities.
  • Provide medical review for identified medical and other non-promotional materials as requested.
  • Maintain current knowledge of the assigned disease state, product, competitors, and other relevant medical and scientific developments.
  • Participate in assigned medical, brand, or company-related meetings as requested.
Desired Qualifications
  • Therapeutic area experience.
  • Clinical, research, or teaching experience.
  • Board certification in the therapeutic area of interest.
  • Completion of a pharmaceutical industry-related residency or fellowship.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.